Can Cell Therapies Cross China’s Border? The Rules Explained September 3, 2026 / Overview / Mike Zhou Can Cell Therapies Cross China’s Border? The Rules Explained Read More »
Can a Hong Kong-Approved Drug Access China’s Greater Bay Area Without Macau Registration? September 3, 2026 / Overview / Mike Zhou Can a Hong Kong-Approved Drug Access China’s Greater Bay Area Without Macau Registration? Read More »
Can Imported Pharmaceuticals Be Repackaged in China? The Answer Depends on Where They Go Next August 20, 2026 / Overview / Mike Zhou Can Imported Pharmaceuticals Be Repackaged in China? The Answer Depends on Where They Go Next Read More »
What Is the Current U.S. WAC Price of OMISIRGE® (omidubicel-onlv)? August 20, 2026 / Overview / Mike Zhou What Is the Current U.S. WAC Price of OMISIRGE® (omidubicel-onlv)? Read More »
Chongqing Opens a Hospital-Led Access Route for Clinically Urgently Needed Imported Medicines and Medical Devices August 6, 2026 / Overview / Mike Zhou Chongqing Opens a Hospital-Led Access Route for Clinically Urgently Needed Imported Medicines and Medical Devices Read More »
Does the GBA Channel Create US MFN Price Exposure? June 13, 2026 / Overview / Mike Zhou Does the GBA Channel Create US MFN Price Exposure? Read More »
Pharmacovigilance in Macau, Hong Kong and Singapore: A Practical Guide to Post-Marketing PV Rules and Processes April 17, 2026 / Overview / Mike Zhou Pharmacovigilance in Macau, Hong Kong and Singapore: A Practical Guide to Post-Marketing PV Rules and Processes Read More »
WODC Sponsor Spotlight: Macau to China in Months, Not Years November 25, 2025 / Overview / Mike Zhou WODC Sponsor Spotlight: Macau to China in Months, Not Years Read More »
2025’s Biggest Shift in Orphan Drugs: Months-Not-Years Access to Greater China October 2, 2025 / Overview / Mike Zhou 2025’s Biggest Shift in Orphan Drugs: Months-Not-Years Access to Greater China Read More »
Named Patient Program Overview for China July 28, 2025 / Overview / Mike Zhou Named Patient Program Overview for China Read More »
